Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03359174 · ClinicalTrials.gov registry record · Phase 2
An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03359174 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 2 participants.
The verdict
NCT03359174, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether a low dose of ATRA will improve laboratory tests of liver and bile duct inflammation in patients with PSC. The investigators will also look for changes to other blood tests which are related to inflammation, scarring, and the immune system.
Interventions
- DRUG All-trans retinoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-05-29 |
| Est. Completion | 2021-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03359174
The ClinicalTrials.gov registry entry for NCT03359174 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which All-trans retinoic acid is the first listed.
NCT03359174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03359174 about?
NCT03359174 is a clinical study titled "An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis". The purpose of this research study is to determine whether a low dose of ATRA will improve laboratory tests of liver and bile duct inflammation in patients with PSC. The investigators will also look for changes to other blood tests which are related to inflammation, scarring, and the immune system.
What is the current status of trial NCT03359174?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2018-05-29. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT03359174?
The interventions under investigation include: All-trans retinoic acid (DRUG).
Who is sponsoring clinical trial NCT03359174?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.